Summary
This paper reports the results of a study organized by theIstituto Superiore di Sanità (Rome, Italy) and carried out in collaboration with several national laboratories. Its aim was to ascertain whether diagnostic kits for detecting anti-HIV antibodies in human serum can also be used to detect the same antibodies in human immunoglobulins. Thirty-three lots of immunoglobulins supplied by six pharmaceutical companies present in Italy were examined using different procedures. On the basis of the results of this study it can be concluded thati. anti-HIV antibodies can be detected in immunoglobulins by means of commercial reagents;ii. a preliminary dilution of immunoglobulin samples should not be made;iii. Western blot method appears to be the ‘reference’ test; however, competitive EIA tests are equally valuable if a negative control made up of anti-HIV-negative Igs is employed;iv. Igs examination for anti-HIV antibody represents an indirect control on a correct donors’ screening procedure.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Benveniste R. E., Ochs H. D., Fischer S. H., Bess J. W. Jr.,Arthur L. O., Wedgwood R. J.: Screening for antibodies to LAV/HTLV-III in recipients of immunoglobulin preparations — Lanceti, 1091, 1986. (Letter).
Bremard-Oury C., Couroucé A. M., Badillet M., Huchet J., Schuller E., Bierling P., Jullien A. M., Habibi B.: Screening for antibodies to LAV/HTLV-III in recipients of immunoglobulin preparations — Lanceti, 1090, 1986. (Letter).
Centers for Disease Control (CDC): Safety of therapeutic immunoglobulin preparations with respect to transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus infection — Morbid. Mortal. wkly Rep.35, 231, 1986.
Centers for Disease Control (CDC): Update: serologic testing for antibody to human immunodeficiency virus — Morbid. Mortal. wkly Rep.36, 833, 1988.
Genesca J., Jett B. W., Epstein J. S., Wai-Kuo Shih J., Hewlett I. K., Alter H. J.: What do Western blot indeterminate patterns for human immunodeficiency virus mean in EIA-negative blood donors? — Lancetii, 1023, 1989.
Gentili G., Wirz M., Collotti C., Vicari G., Tamburrini E., Ortona L.: Anticorpi anti-HIV in preparazioni commerciali di immunoglobuline — Medicina (Rivista EMI)6, 357, 1986.
Gentili G., Wirz M., Collotti C., Vicari G., Tamburrini E., Ortona L.: Anticorpi anti-HIV e immunoglobuline. In:Aiuti F., Moroni M., Pocchiari F. (Eds): AIDS e Sindromi Correlate. Monduzzi editore, Bologna, 1987; p. 1317.
Guidelines on AIDS in Europe. First revised edition. World Health Organization (WHO), Geneva, 1986; p. 1.
Hein R., McCue J., Mozen M. M., Rousell R. H.: Elimination of human immunodeficiency virus from immunoglobulin preparations — Lanceti, 1217, 1986. (Letter).
Piszkiewicz D., Kingdom H., Apfelzweig R., McDougal J. S., Gort S. P., Andrews J., Hope J., Cabridilla C. D.: Inactivation of HTLV-III/LAV during plasma fractionation — Lancetii, 1188, 1985.
Tedder R. S., Uttley A., Cheingsong-Popov R.: Safety of immunoglobulin preparation containing anti-HTLV-III — Lanceti, 815, 1985. (Letter).
Ujhely E., Fust G., Mihaleczky G., Krall G., Nagy K., Mayer V., Hollan S. R.: Studies of the sensitivity and reproducibility of commercial kits to detect antibodies to the human immunodeficiency virus — Transfusion (Philad.)27, 210, 1987.
Wells M. A., Wittek A. E., Epstein J. S., Marcus-Sekura C., Daniel S., Tankersley D. L., Preston M. S., Quinnan G. V. Jr.: Inactivation and partition of human T-cell lymphotropic virus, type III, during ethanol fractionation of plasma — Transfusion (Philad.)26, 210, 1986.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gentili, G., Wirz, M., Collotti, C. et al. Detection of anti-HIV antibodies in preparations of human immunoglobulins. A collaborative group study. Res. Clin. Lab. 20, 95–103 (1990). https://doi.org/10.1007/BF02877555
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02877555